Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma.
Samuel RosnerYuri AgrawalDaniel Q SunNafi AygunMegan D SchollenbergerEvan J LipsonJarushka NaidooPublished in: Journal for immunotherapy of cancer (2021)
Immune checkpoint inhibitors (ICIs) are associated with a range of organ-specific toxicities known as immune-related adverse events (irAEs). Immune-mediated ototoxicity from ICIs is poorly described. Herein, we describe the clinical presentation, diagnostic evaluation and management of six ICI-treated patients who developed immune-mediated ototoxicity, identified by a multidisciplinary immune-related toxicity team. This is the largest case series to date and identifies bilateral high-frequency hearing loss and tinnitus as the most common reported symptoms and can be associated with abnormal speech reception thresholds and word recognition ability on audiogram in select patients. We propose multidisciplinary evaluation of patients with suspected otologic irAEs including referral to otolaryngology, audiometry evaluation±magnetic resonance imaging for evaluation of suspected immune-mediated ototoxicity.
Keyphrases
- high frequency
- hearing loss
- magnetic resonance imaging
- end stage renal disease
- transcranial magnetic stimulation
- newly diagnosed
- chronic kidney disease
- ejection fraction
- quality improvement
- prognostic factors
- computed tomography
- primary care
- genome wide
- palliative care
- peritoneal dialysis
- pulmonary embolism
- patient reported outcomes
- magnetic resonance
- sleep quality
- patient reported
- basal cell carcinoma
- skin cancer